In focus · trending topic

PI3K dual delta/gamma inhibitor

2 stories · following the connections

Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)

By Nasdaq OMXApr 13, 2018, 11:00 AM UTC

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)

By Nasdaq OMXApr 9, 2018, 11:00 AM UTC